Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer (OPERA-02).

Next Previous
Trial Profile

Pivotal Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer (OPERA-02).

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palazestrant (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms OPERA-02

Most Recent Events

  • 28 May 2025 According to an Olema Pharmaceuticals media release, company announced FDA also selected 90 mg of palazestrant in combination with the approved dose of CDK4/6 inhibitor ribociclib for the pivotal Phase 3 OPERA-02 trial
  • 02 Dec 2024 According to an Olema Pharmaceuticals media release, company announces a new clinical trial collaboration and supply agreement with Novartis, under the terms of the agreement, Novartis will provide Olema with ribociclib drug supply for the planned, Olema-sponsored, Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in ER+/HER2- frontline advanced or metastatic breast cancer.
  • 02 Dec 2024 According to an Olema Pharmaceuticals media release, the company expects trial initiation expected in mid-2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top